A new biotech company has been launched with the goal of taking on one of the world’s rarest neurodegenerative…
To continue reading please go to the article on The Pharma Letter
SynaptixBio launched with singular focus
Updated: Dec 16, 2021
Recent Posts
See AllDr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr
1100
SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst
390